Answers are grounded in this paper and cite their sources.
Retrospective study develops a novel risk model using EMT genes to predict survival in breast cancer patients, indicating potential for clinical use.
Background: Accumulating evidence has demonstrated that epithelial-mesenchymal transition (EMT) plays a critical role in breast cancer (BRCA) initiation, invasion, metastasis, and prognosis. Objectives: To develop and validate a comprehensive EMT-related gene signature for robust prognosis prediction in BRCA. Design: Retrospective multi-cohort study. Methods: We obtained 1223 BRCA samples from The Cancer Genome Atlas (TCGA) and 1184 EMT-related genes from the dbEMT2.0 public database. Prognostic genes were selected via univariate Cox and LASSO regression analyses to construct a risk score model, which was subsequently validated in independent internal cohort (TCGA) and external cohorts (UCSC and GEO). Finally, a nomogram integrating the risk score with clinical parameters was established. Results: A 15-gene EMT signature was identified and used to stratify patients into high- and low-risk groups. The high-risk group exhibited significantly poorer overall survival in the TCGA cohort ( P < .05), a finding consistently validated across 4 independent datasets (all P < .05). The risk score served as an independent prognostic factor (hazard ratio = 2.386, P < .001). The integrative nomogram, incorporating the risk score, age, and N and M stages, demonstrated moderate accuracy for survival prediction (C-index = 0.711). Conclusions: We developed and validated a novel 15-gene EMT signature and a corresponding nomogram, which provide a potential tool for prognostic stratification in BRCA patients.
No takes yet. Share an insight, caveat, or question.
Liang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: